Study group – CUP – Carcinoma of Unknown Primary

The study group installs a prospective CUP registry based on a clear-cut definition and subclassification of CUP. This enables the development of novel diagnostic, prognostic and therapeutic options for patients with CUP.

Speaker: Prof. Dr. Kubuschok, Augsburg

Concept & Achievements

Background
- CUP: dismal prognosis and high medical need for new+better therapy
- lack of clear-cut definition and subclassfication, therefore it is:
- difficult to compare data between 6 bavarian university hospitals (UHs) with different diagnostic standards
- diff. to compare therapeutic efficiacy

Concept
- prospective CUP registry (Fig.1)
- clear-cut CUP definition for all UHs
- standardize clinical diagnostics
- harmonize molecular diagnostics
- fix CUP diagnosis in molecular tumor board (MTB)
- digital documentation e.g. Onkostar
- screening platform for experimental and clinical studies

Work Packages (WP)
WP1 Study Protocoll
WP2 Installation of CUP Registry Datasheet and Database
WP3 Collection of Prospective Data
WP4 Collection of Biomaterial
WP5 Collection and Analysis of Retrospective Data for Generation of Scientific Hypothesis/Questions



Fig.1 Prospective Clinical and Molecular Data Registry

Achievements
WP1-2 CUP Registry Database standardized and installed
WP3 Collection of prospective data will start shortly
WP4 Collection of biomaterial started
WP5 Analysis of retrospective data:
1. Preliminary analysis of CUP therapy over the last 3 decades did not show significant improvement in overall survival in Bavarian UHs.
2. Adenocarcinoma of Unknown Primary: Leukocytes and Bilirubin are Prognostic Factors in addition to ECOG and LDH.

Adenocarcinoma of Unknown Primary N = 140	Hazard Ratio	Lower 95% CI	Upper 95% CI	Signifi-cance
Bilirubin total > 1,2 mg/dl	2.44	1.27	4.70	0.007
Leukozyten >10/10e9/l	1.64	1.12	2.36	0.01
LDH > 250 U/ml	1.59	1.05	2.40	0.025
ECOG >= 2	2.36	1.55	3.57	<0.001

Publication
Meyer M., Schenkirsch G., et al., submitted to ESMO Congress 2022 Paris

Integration in the BZKF network
- all 6 sites involved, multidisciplinary team: Pathology, Oncology, Radiotherapy, ENT, Tumor Datamangement, IT
- cooperation with BZKF lighthouse and work groups in multiple research topics e.g. prognostic parameters, pathobiology, new diagnostic and therapeutic tools, therapy monitoring.

Fig.2



Benefits for Patients
- Standardized CUP MTB improves diagnostic accuracy
- CUP registry survival data may help in therapy decisions by data about the efficacy of standard and new therapies
- CUP expert contact persons at the respective UH with knowledge about new diagnostic/therap. tools in BZKF

Future Milestones

- **Collect patients for CUP registry**
- **Characterization of CUP cases by integrated analysis of OMICS data for better prognostic and therapeutic classification – BZKF-MTB discussion**
- **Studies to understand CUP pathobiology**
- **Establish therapy monitoring for detection of tumor progress and resistance**
- **Participate in/initiate clinical phase I/II trials e.g. in the area of theranostics/molecular/immunotherapy**
- **Analyse retrospective data for CUP subgroups**

Authors: UKA: B. Kubuschok, B. Märkl, G. Schenkirsch, UKW: V. Kunzmann, A. Kerscher, UKE: A. Hartmann, V. Brückl, A. Gostian, M. Hecht, R. Fietkau, LMU: B. Westphalen, R. Baumeister, L. Weiss, TUM: S. Pigorsch, F. Schneller, W. Weichert, UKR: M. Grube, M. Vogelhuber, J. Künzel, UR: Ch. Klein. In cooperation with Working Group CUP of the Medical Oncology Association of German Cancer Society

Supported by
Bayerisches Staatsministerium für Wissenschaft und Kunst